INJECTION INDEXWeight management, clearly.
The online care edition
October 2026
Practical guide · October 2026

Semaglutide or Tirzepatide: Start With the Product

Different ingredients, branded medicines, and compounded preparations need a clinical comparison.

Read this firstSources checked October 7, 2026

Use a direct trial for a direct medicine comparison, then bring the result back to individual suitability and access.

Tirzepatide
20.2%

Maximum tolerated 10 or 15 mg weekly study regimen.

Semaglutide
13.7%

Maximum tolerated 1.7 or 2.4 mg weekly study regimen.

Semaglutide and tirzepatide are different ingredients used in prescription treatment. Their presence in an online comparison does not mean either is suitable for every reader. The decision should identify the actual product, its approved use and safety information, and the person’s medical circumstances.

For weight management, Wegovy and Zepbound provide official branded product information. Some online providers also advertise compounded preparations using the ingredient names. The branded and compounded pathways should remain distinct when considering evidence, prescription rationale, and price.

The details, visualized

SURMOUNT-5: direct comparison at 72 weeks

Mean body-weight reduction (%)

  1. Tirzepatide20.2%

    Maximum tolerated 10 or 15 mg weekly study regimen.

  2. Semaglutide13.7%

    Maximum tolerated 1.7 or 2.4 mg weekly study regimen.

Open-label randomized trial in adults with obesity without type 2 diabetes. These are group averages, not personal forecasts or compounded-product evidence. Bars start at zero.

View the printable chart imageSURMOUNT-5: direct comparison at 72 weeks. The same values and context are available in the data table above.
Research note 01

Why a direct comparison is more useful than two unrelated charts

SURMOUNT-5 compared tirzepatide and semaglutide within the same randomized study over 72 weeks. The reported average reductions were 20.2% and 13.7%, a 6.5-percentage-point difference. That is different from subtracting outcomes from separate trials whose participants, methods and follow-up may differ.

The result does not decide the best treatment for every person. Clinical history, tolerability, the approved indication, affordability and the ability to continue follow-up still matter. It also does not show that a compounded preparation or a specific telehealth program will reproduce the branded-product study results.

Before you decide

Questions worth answering

How should I use the chart on this page?

Open-label randomized trial in adults with obesity without type 2 diabetes. These are group averages, not personal forecasts or compounded-product evidence. Bars start at zero.

What should I keep after comparing my options?

Save the named product, the relevant source or agreement, the full payment and renewal details, and the clinician or pharmacy contact. Use the chart as an organizer for questions; it does not replace the selected contract or a medical assessment.

Evidence behind this page

Sources & chart notes

Checked October 7, 2026. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.

Conceptual illustration of a research folio, magnifying lens and two unbranded medicine containers.
Original editorial illustration: connect each claim to the medicine and evidence it describes. The containers are conceptual, not real products.

Use evidence for the product that was studied

Clinical research can inform a discussion of approved medicines, but its findings depend on the studied treatment and population. A reported average is not a prediction for an individual, and it is not proof that a particular provider’s compounded preparation delivers the same outcome.

Read the official Wegovy information or Zepbound information with the clinician. Discuss benefits, contraindications, interactions, adverse effects, and monitoring for the actual proposed medicine rather than selecting an ingredient from an online popularity ranking.

Editorial illustration: an open reference book, a magnifying glass and a document.
Use evidence for the product that was studied — follow the source behind a claim as well as the advertised description.

Separate clinical suitability from convenience

Online access, home delivery, and a published monthly price can make a program easier to compare. They do not determine which ingredient is appropriate for a patient. A clinician needs an accurate history and current medication list before recommending a treatment.

If compounding is considered, ask why an approved product cannot meet your individual needs and what the exact preparation contains. The product-status guide explains why an ingredient headline does not establish FDA approval or equivalence.

Compare the complete treatment cost

Semaglutide and tirzepatide offers may have different prices, supply periods, and care charges. Identify the product and recurring invoice before comparing. An introductory membership number does not necessarily include either medicine.

Use the semaglutide index and tirzepatide index to open provider details, then verify the current quote. The cost guide helps distinguish pharmacy expense from ongoing clinical membership.

Editorial illustration: a calculator, an open purchase ledger and an unbranded container.
Compare the complete treatment cost — compare what the payment covers, when it renews and which charges remain separate.

Have a plan for follow-up

Ask how the treatment is reviewed and how to reach the prescribing team if a concern develops. A changed medicine, shipment issue, or uncertain instruction needs the appropriate clinical or pharmacy contact. Do not use an internet conversion or another patient’s plan to adjust treatment.

The clinical conversation checklist brings these questions together. The useful choice is a clearly identified prescription and support process agreed with a clinician, rather than a universal winner declared by a comparison website.

Use the offer details

Open the CoreAge Rx review, GLP-1 program index, and cost table to continue your comparison. Medical suitability should be discussed with a licensed clinician.

Research record

Documents used

Source register refreshed October 7, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.

  1. FDA: Concerns about unapproved GLP-1 drugs ↗
  2. NIDDK: Prescription medicines for weight management ↗
  3. Wegovy: Official product information ↗
  4. Zepbound: Official product information ↗